KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Work In Process (2022 - 2025)

Historic Work In Process for Sarepta Therapeutics (SRPT) over the last 4 years, with Q3 2025 value amounting to $885.4 million.

  • Sarepta Therapeutics' Work In Process rose 8363.24% to $885.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $885.4 million, marking a year-over-year increase of 8363.24%. This contributed to the annual value of $610.7 million for FY2024, which is 9176.53% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Work In Process stood at $885.4 million for Q3 2025, which was up 8363.24% from $802.9 million recorded in Q2 2025.
  • Sarepta Therapeutics' Work In Process' 5-year high stood at $885.4 million during Q3 2025, with a 5-year trough of $269.2 million in Q4 2022.
  • For the 4-year period, Sarepta Therapeutics' Work In Process averaged around $575.2 million, with its median value being $546.4 million (2024).
  • Its Work In Process has fluctuated over the past 5 years, first soared by 1830.45% in 2023, then surged by 9176.53% in 2024.
  • Sarepta Therapeutics' Work In Process (Quarter) stood at $269.2 million in 2022, then rose by 18.3% to $318.5 million in 2023, then soared by 91.77% to $610.7 million in 2024, then soared by 44.99% to $885.4 million in 2025.
  • Its Work In Process stands at $885.4 million for Q3 2025, versus $802.9 million for Q2 2025 and $762.2 million for Q1 2025.